POTENTIATION OF ANTI-CANCER AGENT CYTOTOXICITY AGAINST SENSITIVE AND RESISTANT AKR LEUKEMIA BY AMPHOTERICIN-B
- 1 January 1979
- journal article
- research article
- Vol. 39 (6), 2041-2045
Abstract
Amphotericin B was able to enhance the effects of actinomycin D (Act-D), adriamycin and vincristine against AKR leukemia. AKR leukemia lines of increasing resistance to Act-D were obtained by passage in syngeneic mice treated with Act-D. The cells selected for Act-D resistance also eventually became cross-resistant to vincristine and adriamycin, but resistance to these agents developed at a slower rate. Amphotericin B enhanced the effects of all these agents against the resistant cells, although the degree of enhancement varied among these antitumor agents and decreased as drug resistance increased in the late-passage leukemia lines.This publication has 5 references indexed in Scilit:
- Growth and Rejection of Leukemia Cells in Individual Mice After Combined Treatment With Amphotericin B and 1,3-Bis(2-chloroethyl)-1-nitrosourea2JNCI Journal of the National Cancer Institute, 1978
- Response of Transplanted AKR Leukemia to Combination Therapy With Amphotericin Band 1,3-Bis(2-chloroethyl)-1-nitrosourea: Dose and Schedule Dependency2JNCI Journal of the National Cancer Institute, 1977
- DECREASED RETENTION OF ACTINOMYCIN-D AS BASIS FOR CROSS-RESISTANCE IN ANTHRACYCLINE-RESISTANT SUBLINES OF P388 LEUKEMIA1977
- Amphotericin B Induction of Sensitivity to Adriamycin, 1,3-bis (2-Chloroethyl)-1-Nitrosourea (BCNU) plus Cyclophosphamide in Human NeoplasiaAnnals of Internal Medicine, 1977
- USE OF LIPID VESICLES AS CARRIERS TO INTRODUCE ACTINOMYCIN-D INTO RESISTANT TUMOR-CELLS1976